BlossomHill Therapeutics, Inc.'s next confirmed earnings release is scheduled for March 3, 2027.
| Earnings Date | 3/3/2027 |
As of June 30, 2026, BlossomHill Therapeutics, Inc. has 30.64M shares outstanding.
| Shares Outstanding | 30.64M |
As of June 30, 2026, BlossomHill Therapeutics, Inc. maintains a current ratio of 5.42, meaning it holds 5.4x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 5.42 |
| Quick Ratio | 5.12 |
| Debt / Equity | -13.37 |
These figures cover the twelve months ended June 30, 2026. The company generates approximately - - in revenue per employee across its workforce of 63.00, a quick read on workforce productivity versus industry peers.
| Employee Count | 63.00 |
These figures are as of the close on November 16, 2026.
| 50-Day Moving Average | 17.84 |
These figures cover the twelve months ended June 30, 2026.
| Pretax Income | -23.76M |
As of June 30, 2026, BlossomHill Therapeutics, Inc. holds 95.38M in cash and equivalents against 23.37M in total debt, resulting in a net debt position of -95.38M. Total book value stands at -174.78M, with working capital of 82.35M providing operational flexibility.
| Cash & Cash Equivalents | 95.38M |
| Total Debt | 23.37M |
| Net Debt | -95.38M |
| Equity (Book Value) | -174.78M |
| Book Value Per Share | -5.70 |
| Working Capital | 82.35M |
These figures cover the twelve months ended June 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled -23.23M - equivalent to -0.80 per share.
| Free Cash Flow | -23.23M |
| FCF Per Share | -0.80 |